DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease | MicrobiomeTrials← Back to trialsNCT06918808
DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-05-19Est. Completion: 2027-07-30
Enrollment target: 36 participants Locations- Direct Biologics Investigational Site, Aurora, Colorado, United States
- Direct Biologics Investigational Site, St Louis, Missouri, United States
- Columbia University Irving Medical Center/NYPH, New York, New York, United States
- Direct Biologics Investigational Site, Philadelphia, Pennsylvania, United States
- Direct Biologics Investigational Site, Nashville, Tennessee, United States
Other microbiome trials you might be interested in
Fistulizing Crohns DiseasePerianal Crohns Disease
The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn's disease and t…
Birmingham, United StatesEst. completion Mar 25, 2027
Ileal PouchCrohn Disease
Restorative proctocolectomy with ileal pouch anal anastomosis (IPAA) is the procedure of choice for patients with ulcera…
Cleveland, United StatesCompleted Nov 15, 2023